Filing Flows › Impact Biomedical (IBO) › Guidance & outlook
Impact Biomedical (IBO) guidance and outlook
Impact Biomedical's 10-Q filed Nov 9, 2026 makes 3 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 9, 2026
- The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern.
- The Company’s management intends to take additional actions necessary to continue as a going concern.
- GAAP requires management to make judgments, assumptions and estimates that affect the amounts reported in our financial statements and accompanying notes.
Impact Biomedical's latest quarter
Impact Biomedical, Q3 2026: revenue $21K (+17% year over year), net loss $644K, operating cash flow $11K. The chart follows the revenue to costs, profit and cash.
Questions
What does Impact Biomedical expect?
The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company’s management intends to take additional actions necessary to continue as a going concern. GAAP requires management to make judgments, assumptions and estimates that affect the amounts reported in our financial statements and accompanying notes.
Updated Nov 9, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.